<?xml version="1.0" encoding="UTF-8"?>
<p>Because anti-COVID-19 therapy was protocolized in the SOP, in general PLWH received similar anti-COVID-19 therapy as other non-HIV-infected patients. This meant that antiretroviral therapy was temporarily switched to a regimen that included lopinavir/ritonavir unless otherwise contraindicated. We are unable to provide further data on the efficacy of this strategy against COVID-19 in PLWH. As in the general population, some PLWH with a worse clinical evolution also received other drugs including IFN-1Î², glucocorticoids, and tociluzimab according to SOP [
 <xref rid="R31" ref-type="bibr">31</xref>,
 <xref rid="R32" ref-type="bibr">32</xref>].
</p>
